StockNews.AI
ASBP
StockNews.AI
112 days

Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

1. Aspire Biopharma received IRB approval for its Phase I clinical trial. 2. Trial for a novel high-dose aspirin formulation begins this week.

2m saved
Insight
Article

FAQ

Why Bullish?

The IRB approval and initiation of clinical trials are positive indicators. Previous similar events for biotech firms often led to price increases as milestones are achieved.

How important is it?

The approval and trial start are crucial developments for ASBP's growth. Investor confidence may rise, impacting stock valuation.

Why Short Term?

The trial results may be available soon, impacting stock price rapidly. Immediate investor interest in trial progression is anticipated.

Related Companies

AXGENCTICINFI
Company achieves another milestone relating to its clinical trial strategy HUMACAO, PR and NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that it has received Institutional Review Board (IRB) approval of the clinical trial protocol for its upcoming Phase I single-center clinical trial in the United States designed to evaluate safety, pharmacokinetics and pharmacodynamics, of its lead therapeutic candidate, an oral transmucosal fast-acting high-dose aspirin formulation. One clinical trial site has been activated with patient enrollment expected to total six to eight participants and the trials are expected to begin this week.

Related News